why choose us

First received: May 26, 2023

Clinical Trial: Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Brief Summary: This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma.[89Zr]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer.A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body.[89Zr]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and…

Read more